Tag Archives:Prostate cancer
Treating prostate cancer with immunotherapy
Cancer immunotherapy induces the immune system to recognize and destroy cancer cells. These therapies can work through a number of ways but two of the most researched methods are therapeutic cancer vaccines and immune checkpoint inhibitors. Therapeutic
A novel radionuclide treatment for hormone refractory metastatic prostate cancer
Prostate cancer is the second most common male cancer worldwide and the fourth most common cancer overall. In patients with localized prostate cancer, the five-year survival rate approximates to 100%; however, in patients with distant metastases, it
Treatment sequencing in metastatic castrate-resistant prostate cancer
The treatment of metastatic castrate resistant prostate cancer (mCRPC) has been rapidly advancing. Years of research effort have culminated, in the approvals of five active agents that prolong patient survival. However, as a practicing clinician, I and
Prostate cancer: prognostic impact of adenosine-generating CD73
Traditionally, most cancers were treated with surgery, radiotherapy or chemotherapy (or a combination of these options). Using the immune system to fight cancer has long been the objective of many researchers, but convincing success in the clinic
Regucalcin may prevent the development of prostate age-related pathologies such as prostate cancer
Regucalcin (RGN) is a protein with a multifunctional role, which regulates the basic biological processes determining cell fate. RGN actions have been implicated in the control of intracellular calcium levels, oxidative stress, cell metabolism, cell death and
Gene expression changes underlying prostate cancer metastasis
Prostate cancer is one of the most common cancers among men. The American Cancer Society estimates that there will be 220,800 new cases of prostate cancer in 2015 and 27,540 prostate cancer related deaths. The National Cancer
The risk of death from high-risk prostate cancer in men undergoing EBRT and brachytherapy
According to the National Comprehensive Cancer Network (NCCN) guidelines, treatment with long-course (28–36 months) androgen deprivation therapy (ADT), in addition to brachytherapy (where radioactive seeds are implanted inside the prostate to kill cancer cells) and external beam radiation
